Back to Search

A Phase 1/2 Open-label, Biomarker-defined Cohort Trial to Evaluate the Safety, Determine the Recommended Combination Dosing, and Assess Early Antitumor Activity of Tipifarnib and Alpelisib for the Treatment of Adult Participants Who Have HRAS-overexpressing and/or PIK3CA-mutated and/or - Amplified Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Protocol Number: 202108011
  • Principal Investigator: Adkins, Douglas
  • Cancer Types: Head & Neck

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions